Alector Inc. (ALEC)

Biological Products, (No Diagnostic Substances) · market cap $221M · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Alector Inc. (ALEC) is a 156-employee clinical-stage biotech focused on neurodegeneration, with a Phase 3 asset (AL001) in Frontotemporal Dementia and a Phase 2 asset (AL002) in Alzheimer's Disease. At a ~$179M market cap and $1.61/share, the company carries approximately $77M in cash against a stated 4.6-month runway, implying an urgent capital need before year-end 2026.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
AL002	Phase 2	Alzheimer Disease
AL001	Phase 3	Frontotemporal Dementia
GSK4527226	Phase 2	Alzheimer's Disease

Price & technical context

3-month

-9.7%

6-month

-26.5%

12-month

-37.2%

52-wk range

$1.14–$3.32

vs 50-day MA

-7.5%

vs 200-day MA

-6.5%

Realized vol

105.1%

Max drawdown

-85.3%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ALEC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.